arrow
M

Maddalena Sansovini

IRCCS Istituto Romagnolo per lo Studio dei Tumori Dino Amadori
H指数:25
被引数:2,792

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Baseline serum carcinoembryonic antigen (CEA) is an independent prognostic biomarker for metastatic castration-resistant prostate cancer (mCRPC) patients receiving 177Lu-PSMA therapy

基线血清癌胚抗原(CEA)是接受177Lu-PSMA治疗的转移性去势抵抗性前列腺癌(mCRPC)患者的独立预后生物标志物

2026-09-110
OAAI
Post-VABB Cavity-Targeted Avidin-Pretargeted [90Y]Y-DOTA-Biotin in Nonpalpable Breast Cancer: A Phase I Activity-Escalation Study (ARTHE)

术后VABB腔内靶向亲和素预靶向[90Y]Y-DOTA-生物素在非可触及乳腺癌中的应用:一项I期剂量递增研究(ARTHE)

Cancers
IF4.4
2026-08-280
OA
[177Lu]Lu-DOTA-TATE plus long-acting octreotide in patients with newly diagnosed, advanced, grade 2–3, gastroenteropancreatic neuroendocrine tumours: preplanned and post-hoc efficacy analyses from the randomised, phase 3 NETTER-2 trial

[177Lu]Lu-DOTA-TATE联合长效奥曲肽治疗新诊断的、进展期、2-3级胃肠胰腺神经内分泌肿瘤患者的疗效分析:来自随机III期NETTER-2试验的预先计划和事后分析

2026-08-070
OA
Efficacy, toxicity, and clinical outcomes of 177Lu-PSMA-617 radioligand therapy at 5.5 GBq per cycle in patients with advanced castration-resistant prostate cancer: a prospective, single arm, phase II study

177Lu-PSMA-617放射性配体疗法的疗效、毒性和临床结局:一项前瞻性、单臂、II期研究,研究对象为每周期接受5.5 GBq剂量的晚期去势抵抗性前列腺癌患者

2025-11-270
OAAI
Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project

关于α-粒子疗法临床应用及未来潜力的建议:SECURE项目结果的全面综述

2025-10-180
OAAI
A Randomized clinical trial evaluating the impact on survival and quality of life of 177Lutetium[Lu]-edotreotide versus everolimus in patients with neuroendocrine tumors of the lung and thymus: the LEVEL study (GETNE T-2217)
2025-04-040
OAAI
Treatments and Outcomes in Neuroendocrine Patients Treated with Long-Acting Somatostatin Analogues: An Italian Real-World Propensity Score-Matched Cohort Study

长效生长抑素类似物治疗神经内分泌患者的治疗和结局: 一项意大利真实世界倾向评分匹配队列研究

2025-02-190
OAAI
Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)

开放标签、多中心随机试验,比较镭223-多西他赛与多西他赛-镭223序贯疗法在转移性去势抵抗性前列腺癌(mCRPC)中的应用(并前瞻性评估生物标志物)(RAPSON研究)

2024-09-010
PRE
Lutetium [177Lu]-DOTA-TATE in gastroenteropancreatic-neuroendocrine tumours: rationale, design and baseline characteristics of the Italian prospective observational (REAL-LU) study
2024-05-220
OAAI
Radioligand therapies in cancer: mapping the educational landscape in Europe
2023-04-142
OAAI
HRAS overexpression predicts response to Lenvatinib treatment in gastroenteropancreatic neuroendocrine tumors
2023-01-203
OAAI
Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

嗅神经母细胞瘤中生长抑素受体2的临床结果,kdish-insica分期和治疗靶点

2022-02-0136
OAAI